Lessons learned from COVID-19 pandemic: Vaccine platform is a key player

Area of Science:

• Vaccinology and Immunology
• Infectious Disease Preparedness
• Biotechnology and Pharmaceutical Sciences

Background:

• The SARS-CoV-2 pandemic necessitated rapid vaccine development, highlighting the importance of diverse technological platforms.
• Conventional vaccine platforms (inactivated, subunit, VLPs) have a proven track record, while novel platforms (viral vector, nucleic acid) offer new possibilities.

Purpose of the Study:

• To review lessons learned from COVID-19 vaccine development regarding platform selection and rapid translation.
• To emphasize the critical role of vaccine platform characteristics, including storage, shipping, and distribution, in pandemic response.
• To explore the potential repurposing of COVID-19 vaccine platforms for non-infectious diseases.

Main Methods:

• Comprehensive review of scientific literature and public health data related to COVID-19 vaccine development.
• Analysis of the advantages and disadvantages of various vaccine platforms in the context of pandemic response.
• Evaluation of logistical factors influencing vaccine deployment and accessibility.

Main Results:

• Novel vaccine platforms, particularly nucleic acid-based ones, demonstrated rapid development potential.
• Successful pandemic response requires parallel development of multiple platforms and robust logistical planning (storage, shipping, distribution).
• Existing COVID-19 vaccine platforms show promise for applications beyond infectious diseases.

Conclusions:

• Vaccine platform choice is crucial for rapid response to emerging infectious diseases.
• Logistical considerations are paramount for equitable and effective vaccine distribution during pandemics.
• The versatility of current vaccine technologies may extend to treating non-infectious conditions.